Contact
← All workflows

Material Transfer Agreement (Biological)

Draft Biological Material Transfer Agreements in Minutes

12 minutes with CaseMark

Fast lane

We have it from here.

Choose the fast one-off run here, or jump into the workspace when you want saved history, revisions, and a fuller matter workflow.

Run this once here

Best for a quick one-off job. Add your email, upload the files, and we'll run the workflow and send the result to your inbox.

1. Add your email so we know where to send the result.

2. Upload the files you want analyzed.

3. Run the workflow and we'll take it from there.

Use in Workspace

Best for ongoing matters

Save and reopen matters, keep documents together, refine the output, rerun with changes, and export or share polished work product when you're done.

Open in Workspace

Need more context?

Scroll for the workflow details below if you want to review what this run handles, what documents help, and what the output looks like.

If this is part of a live matter, the workspace is the better fit: you can keep your documents together, revisit the result, and keep working without starting from scratch.

Jump to detailsOpen in Workspace

Start here

Run this workflow now

Best for a fast one-off run. Add your email, upload the files, and we'll deliver the result without sending you into the full app.

Workflow

Material Transfer Agreement (Biological)

Step 1 · Deliver to

Step 3 · Run this workflow

Workflow

Material Transfer Agreement (Biological)

Overview

Drafting Material Transfer Agreements for biological materials requires extensive knowledge of NIH guidelines, FDA regulations, IP protections, and biosafety standards. Attorneys spend hours researching compliance requirements, adapting templates from AUTM or university resources, and ensuring proper liability protections—all while coordinating with research institutions and technology transfer offices.

Material Transfer Agreements for biological materials require balancing complex regulatory compliance, biosafety requirements, IP allocation, and institutional policies. Manual drafting takes hours of specialized legal expertise to address NIH guidelines, export controls, select agent regulations, and technology transfer frameworks while protecting both parties' interests.

CaseMark automates the entire MTA drafting process, generating comprehensive, legally sound agreements that address biosafety classification, regulatory compliance, IP ownership, publication rights, and institutional requirements. Our AI ensures every provision meets NIH UBMTA standards, Bayh-Dole Act requirements, and export control regulations while customizing terms to your specific materials and research context.

How it works

  1. 1. Upload your documents

  2. 2. AI analyzes and extracts key information

  3. 3. Review and customize the generated content

  4. 4. Export in your preferred format (DOCX, PDF)

What you get

  • Parties

  • Description of Materials

  • Transfer Terms

  • Permitted Use and Restrictions

  • Confidentiality

  • Intellectual Property Rights

  • Liability and Warranties

  • Indemnification

  • Termination and Return of Materials

  • Governing Law and Dispute Resolution

  • Signatures

What it handles

  • Parties

  • Description of Materials

  • Transfer Terms

  • Permitted Use and Restrictions

  • Confidentiality

  • Intellectual Property Rights

  • Liability and Warranties

  • Indemnification

  • Termination and Return of Materials

  • Governing Law and Dispute Resolution

  • Signatures

Required documents

  • Material Specifications

    Scientific description of biological materials including strain, biosafety level, genetic modifications, and regulatory status

    PDF, DOCX, TXT

  • Party Information

    Complete legal names, addresses, and authorized representatives for Provider and Recipient organizations

    PDF, DOCX, TXT

Supporting documents

  • Research Protocol

    Detailed description of intended research use and objectives for the biological materials

    PDF, DOCX

  • Upstream MTA

    Any existing material transfer agreements with third-party restrictions on the materials

    PDF, DOCX

  • Institutional Policies

    Technology transfer policies, biosafety requirements, or institutional guidelines that must be incorporated

    PDF, DOCX

  • Export Control Assessment

    Export control classification and licensing requirements for international transfers

    PDF, DOCX

Why teams use it

Generate NIH-compliant MTAs in 12 minutes vs. 4.5 hours manually

Automatic integration of AUTM best practices and university policy standards

Built-in IP protection clauses verified against bar association resources

Intelligent extraction of material specifications and hazard classifications from uploaded documents

Comprehensive liability, indemnification, and warranty provisions tailored to biological transfers

Questions

What makes a Material Transfer Agreement for biological materials different from other MTAs?

Biological MTAs must address unique regulatory frameworks including biosafety levels, select agent regulations, NIH guidelines for recombinant DNA, and export controls specific to biological materials. They require detailed provisions on derivatives and progeny, special handling and shipping requirements for viable organisms, and careful IP allocation that complies with the Bayh-Dole Act for federally funded research. CaseMark automatically incorporates all these specialized requirements based on your material specifications.

How does CaseMark handle intellectual property rights in biological MTAs?

CaseMark creates sophisticated IP provisions that distinguish between the original materials, unmodified progeny, derivatives with substantial modifications, and inventions made using the materials. The system allocates ownership rights consistent with Bayh-Dole Act requirements for federally funded research while protecting provider interests through options, reach-through rights, or licensing provisions. You can customize the IP framework based on whether parties are academic institutions, commercial entities, or mixed collaborations.

Can CaseMark ensure compliance with biosafety and export control regulations?

Yes, CaseMark automatically generates compliance provisions based on the biosafety level and regulatory status you specify. The system incorporates appropriate biosafety containment requirements, select agent transfer procedures if applicable, export control representations and licensing obligations, and institutional biosafety committee approval requirements. All regulatory provisions are updated to reflect current CDC, NIH, ITAR, and EAR requirements.

How does CaseMark balance publication rights with confidentiality in research MTAs?

CaseMark creates balanced publication review provisions that respect academic freedom while protecting proprietary interests. The system establishes reasonable review periods (typically 30-60 days), limits provider review rights to confidentiality protection and patent filing rather than censorship, and includes maximum delay periods for patent applications. These provisions comply with institutional policies at major research universities while giving providers necessary IP protection.

What happens to materials and derivatives when an MTA terminates?

CaseMark generates comprehensive post-termination provisions requiring cessation of use, return or destruction of materials, and certification of compliance. The system addresses retention of samples for regulatory compliance, survival of confidentiality and IP provisions, and wind-down periods for completing ongoing experiments. You can customize whether derivatives created by the recipient remain subject to restrictions or whether the recipient retains certain rights after termination.

Related

510k Premarket Notification

Draft FDA 510(k) Submissions in Minutes, Not Hours

Adverse Event Reporting Policy

Draft FDA-Compliant Adverse Event Policies in Minutes

Anti-Money Laundering (AML) Compliance Program

Draft AML Compliance Programs in Minutes, Not Days